HC Wainwright Brokers Boost Earnings Estimates for LENZ

Key Points

• HC Wainwright has increased its Q3 2025 earnings per share (EPS) estimate for LENZ Therapeutics from ($0.82) to ($0.67), while maintaining a "Buy" rating with a target price of $48.00.
• Other analysts have also raised their price targets, with Piper Sandler setting a price target of $51.00 and Citigroup increasing theirs to $49.00, reflecting strong confidence in the company's performance.
• LENZ Therapeutics reported a revenue of $5 million last quarter, exceeding estimates, and has a market capitalization of approximately $854.46 million.

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of LENZ Therapeutics in a research note issued on Thursday, July 31st. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.67) per share for the quarter, up from their previous estimate of ($0.82). HC Wainwright currently has a "Buy" rating and a $48.00 target price on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($2.76) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at $0.97 EPS and FY2029 earnings at $2.11 EPS.

A number of other equities research analysts have also recently weighed in on LENZ. Piper Sandler assumed coverage on LENZ Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $51.00 price target for the company. Citigroup raised their target price on LENZ Therapeutics from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Raymond James Financial lifted their price target on LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of "Buy" and an average target price of $49.60.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $29.96 on Monday. The company has a market capitalization of $854.46 million, a P/E ratio of -15.77 and a beta of 0.42. LENZ Therapeutics has a one year low of $16.53 and a one year high of $38.93. The business's 50 day simple moving average is $31.03 and its 200-day simple moving average is $27.01.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.05. The firm had revenue of $5.00 million for the quarter, compared to the consensus estimate of $5.00 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP bought a new stake in shares of LENZ Therapeutics during the fourth quarter worth $22,243,000. Adage Capital Partners GP L.L.C. bought a new stake in LENZ Therapeutics during the 1st quarter worth about $13,825,000. Price T Rowe Associates Inc. MD raised its holdings in LENZ Therapeutics by 83.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock worth $23,760,000 after purchasing an additional 374,326 shares during the last quarter. Granahan Investment Management LLC lifted its position in LENZ Therapeutics by 239.8% during the 1st quarter. Granahan Investment Management LLC now owns 176,166 shares of the company's stock valued at $4,529,000 after purchasing an additional 124,324 shares during the period. Finally, Scoggin Management LP bought a new position in shares of LENZ Therapeutics in the 1st quarter valued at about $2,571,000. Institutional investors and hedge funds own 54.32% of the company's stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.